• Something wrong with this record ?

Autoregulation of Pulsatile Bioprosthetic Total Artificial Heart is Involved in Endothelial Homeostasis Preservation

DM. Smadja, R. Chocron, E. Rossi, B. Poitier, Y. Pya, M. Bekbossynova, C. Peronino, J. Rancic, JC. Roussel, M. Kindo, N. Gendron, L. Migliozzi, A. Capel, JC. Perles, P. Gaussem, P. Ivak, P. Jansen, C. Girard, A. Carpentier, C. Latremouille, C....

. 2020 ; 120 (9) : 1313-1322. [pub] 20200720

Language English Country Germany

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21026604

Pulsatile Carmat bioprosthetic total artificial heart (C-TAH) is designed to be implanted in patients with biventricular end-stage heart failure. Since flow variation might contribute to endothelial dysfunction, we explored circulating endothelial biomarkers after C-TAH implantation in seven patients and compared the manual and autoregulated mode. Markers of endothelial dysfunction and regeneration were compared before and during a 6- to 9-month follow-up after implantation. The follow-up was divided into three periods (< 3, 3-6, and > 6 months) and used to estimate the temporal trends during the study period. A linear mixed model was used to analyze repeated measures and association between tested parameters according to the mode of C-TAH and the time. Relevance of soluble endoglin (sEndoglin) level increase has been tested on differentiation and migration potential of human vasculogenic progenitor cells (endothelial colony forming cells [ECFCs]). Normal sEndoglin and soluble endothelial protein C receptor (sEPCR) levels were found in patients after implantation with autoregulated C-TAH, whereas they significantly increased in the manual mode, as compared with pretransplant values (p = 0.005 and 0.001, respectively). In the autoregulated mode, a significant increase in the mobilization of cytokine stromal cell-derived factor 1 was found (p = 0.03). After adjustment on the mode of C-TAH, creatinine or C-reactive protein level, sEndoglin, and sEPCR, were found significantly associated with plasma total protein levels. Moreover, a significant decrease in pseudotubes formation and migration ability was observed in vitro in ECFCs receiving sEndoglin activation. Our combined analysis of endothelial biomarkers confirms the favorable impact of blood flow variation achieved with autoregulation in patients implanted with the bioprosthetic total artificial heart.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026604
003      
CZ-PrNML
005      
20211026132753.0
007      
ta
008      
211013s2020 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1055/s-0040-1713751 $2 doi
035    __
$a (PubMed)32688422
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Smadja, David M $u Inserm UMR-S 1140, Innovative Therapies in Haemostasis, Service d'Hématologie et Laboratoire de Recherches Biochirugicales (Fondation Carpentier), Université de Paris, Georges Pompidou European Hospital, Paris, France
245    10
$a Autoregulation of Pulsatile Bioprosthetic Total Artificial Heart is Involved in Endothelial Homeostasis Preservation / $c DM. Smadja, R. Chocron, E. Rossi, B. Poitier, Y. Pya, M. Bekbossynova, C. Peronino, J. Rancic, JC. Roussel, M. Kindo, N. Gendron, L. Migliozzi, A. Capel, JC. Perles, P. Gaussem, P. Ivak, P. Jansen, C. Girard, A. Carpentier, C. Latremouille, C. Guerin, I. Netuka
520    9_
$a Pulsatile Carmat bioprosthetic total artificial heart (C-TAH) is designed to be implanted in patients with biventricular end-stage heart failure. Since flow variation might contribute to endothelial dysfunction, we explored circulating endothelial biomarkers after C-TAH implantation in seven patients and compared the manual and autoregulated mode. Markers of endothelial dysfunction and regeneration were compared before and during a 6- to 9-month follow-up after implantation. The follow-up was divided into three periods (< 3, 3-6, and > 6 months) and used to estimate the temporal trends during the study period. A linear mixed model was used to analyze repeated measures and association between tested parameters according to the mode of C-TAH and the time. Relevance of soluble endoglin (sEndoglin) level increase has been tested on differentiation and migration potential of human vasculogenic progenitor cells (endothelial colony forming cells [ECFCs]). Normal sEndoglin and soluble endothelial protein C receptor (sEPCR) levels were found in patients after implantation with autoregulated C-TAH, whereas they significantly increased in the manual mode, as compared with pretransplant values (p = 0.005 and 0.001, respectively). In the autoregulated mode, a significant increase in the mobilization of cytokine stromal cell-derived factor 1 was found (p = 0.03). After adjustment on the mode of C-TAH, creatinine or C-reactive protein level, sEndoglin, and sEPCR, were found significantly associated with plasma total protein levels. Moreover, a significant decrease in pseudotubes formation and migration ability was observed in vitro in ECFCs receiving sEndoglin activation. Our combined analysis of endothelial biomarkers confirms the favorable impact of blood flow variation achieved with autoregulation in patients implanted with the bioprosthetic total artificial heart.
650    _2
$a senioři $7 D000368
650    _2
$a biologické markery $x analýza $7 D015415
650    12
$a bioprotézy $7 D001705
650    _2
$a endoglin $x analýza $7 D000071063
650    _2
$a endoteliální receptor proteinu C $x analýza $7 D000074283
650    _2
$a endotel $x patologie $7 D004727
650    _2
$a následné studie $7 D005500
650    _2
$a srdeční selhání $x terapie $7 D006333
650    12
$a umělé srdce $7 D006354
650    _2
$a homeostáza $7 D006706
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
655    _2
$a časopisecké články $7 D016428
700    1_
$a Chocron, Richard $u Inserm UMR-S 970 PARCC, Service d'urgences, Université de Paris, Georges Pompidou European Hospital, Paris, France
700    1_
$a Rossi, Elisa $u Innovative Therapies in Haemostasis, Université de Paris, Paris, France
700    1_
$a Poitier, Bastien $u Innovative Therapies in Haemostasis, Service de Chirurgie Cardiaque et Laboratoire de Recherches Biochirugicales (Fondation Carpentier), Université de Paris, Georges Pompidou European Hospital, Paris, France
700    1_
$a Pya, Yuri $u National Research Cardiac Surgery Center, Astana, Kazakhstan
700    1_
$a Bekbossynova, Mahabbat $u National Research Cardiac Surgery Center, Astana, Kazakhstan
700    1_
$a Peronino, Christophe $u Inserm UMR-S 1140, Innovative Therapies in Haemostasis, Service d'Hématologie et Laboratoire de Recherches Biochirugicales (Fondation Carpentier), Université de Paris, Georges Pompidou European Hospital, Paris, France
700    1_
$a Rancic, Jeanne $u Inserm UMR-S 1140, Innovative Therapies in Haemostasis, Service d'Hématologie et Laboratoire de Recherches Biochirugicales (Fondation Carpentier), Université de Paris, Georges Pompidou European Hospital, Paris, France
700    1_
$a Roussel, Jean Christian $u Service de Chirurgie Thoracique et Cardiovasculaire, Unité de transplantation thoracique, CHU de Nantes, Hôpital Nord Laënnec, Saint-Herblain, Nantes Cedex 1, France
700    1_
$a Kindo, Michel $u Service de Chirurgie Cardiovasculaire, NHC - Hôpital Civil, Hôpitaux Universitaires de Strasbourg, 1, Place de L'Hôpital, Strasbourg, Cedex, France
700    1_
$a Gendron, Nicolas $u Inserm UMR-S 1140, Innovative Therapies in Haemostasis, Service d'Hématologie et Laboratoire de Recherches Biochirugicales (Fondation Carpentier), Université de Paris, Georges Pompidou European Hospital, Paris, France
700    1_
$a Migliozzi, Ludovica $u Innovative Therapies in Haemostasis, Service de Chirurgie Cardiaque et Laboratoire de Recherches Biochirugicales (Fondation Carpentier), Université de Paris, Georges Pompidou European Hospital, Paris, France
700    1_
$a Capel, Antoine $u Carmat SAS, Velisy-Villacoublay, France
700    1_
$a Perles, Jean Christophe $u Carmat SAS, Velisy-Villacoublay, France
700    1_
$a Gaussem, Pascale $u Innovative Therapies in Haemostasis, Service d'Hématologie, Université de Paris, Georges Pompidou European Hospital, Paris, France
700    1_
$a Ivak, Peter $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Jansen, Piet $u Carmat SAS, Velisy-Villacoublay, France
700    1_
$a Girard, Claude $u Unité d'Anesthesie Réanimation Cardio-Vasculaire, CHU François Mitterrand, Dijon Cedex, France
700    1_
$a Carpentier, Alain $u Innovative Therapies in Haemostasis, Université de Paris, Paris, France
700    1_
$a Latremouille, Christian $u Innovative Therapies in Haemostasis, Service de Chirurgie Cardiaque et Laboratoire de Recherches Biochirugicales (Fondation Carpentier), Université de Paris, Georges Pompidou European Hospital, Paris, France
700    1_
$a Guerin, Coralie $u Innovative Therapies in Haemostasis, Plateforme de Cytométrie, Institut Curie, Université de Paris, Paris, France
700    1_
$a Netuka, Ivan $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
773    0_
$w MED00004517 $t Thrombosis and haemostasis $x 2567-689X $g Roč. 120, č. 9 (2020), s. 1313-1322
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32688422 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132800 $b ABA008
999    __
$a ok $b bmc $g 1715360 $s 1147111
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 120 $c 9 $d 1313-1322 $e 20200720 $i 2567-689X $m Thrombosis and haemostasis $n Thromb Haemost $x MED00004517
LZP    __
$a Pubmed-20211013
Back

Find record

Citation metrics

Archiving options